For decades, "getting Botox" was the universal shorthand for wrinkle-relaxing injections. But the landscape has fundamentally changed. By 2026, the U.S. FDA has approved six distinct botulinum toxin type A products for cosmetic use — and four of them are now head-to-head competitors in the fastest-growing segment of medical aesthetics.
Letybo, Dysport, Xeomin, and Daxxify each promise smoother skin, fewer wrinkles, and a more rested appearance. But they are not the same product. They differ in formulation chemistry, onset speed, duration of effect, cost structure, ideal treatment areas, and even the type of patient who benefits most from each.
This guide cuts through the marketing language and gives you what you actually need: real clinical data, honest cost comparisons, expert perspectives, and a clear framework for deciding which neurotoxin makes sense for your face, budget, and lifestyle.
What Are Neuromodulators and How Do They Work?
Before diving into brand-specific differences, a quick primer on the science.
All four injectables in this guide — Letybo, Dysport, Xeomin, and Daxxify — work through the same core mechanism. When injected into a facial muscle, botulinum toxin type A blocks the release of acetylcholine, the neurotransmitter responsible for triggering muscle contractions. With the nerve-muscle communication temporarily interrupted, the muscle relaxes, and the overlying skin smooths out.
This is why they're called "neuromodulators" rather than simply "fillers." They don't add volume — they modify nerve signals.
What varies between products is everything around that core molecule: the stabilizing proteins attached to it, the peptide or carrier technology used, the purity of the formula, and how the body ultimately metabolizes each version. Those differences are what drive the real-world distinctions in speed, longevity, spread, and price.
The Four Contenders: A Quick Introduction
Letybo (LetibotulinumtoxinA-wlbg)
Manufactured by South Korean company Hugel Inc., Letybo received FDA approval in February 2024, making it the sixth botulinum toxin to achieve this milestone globally. It's been the dominant neurotoxin brand in South Korea for seven consecutive years under the name Botulax. Its FDA approval was supported by results from three Phase III clinical trials (the BLESS studies) enrolling more than 1,000 subjects across the U.S. and Europe.
Letybo's defining characteristic is its formulation with fewer complexing proteins than competitors like Botox. Fewer proteins mean fewer targets for the immune system to build antibodies against — a meaningful advantage for long-term users who worry about developing resistance.
Dysport (AbobotulinumtoxinA)
Manufactured by Ipsen and distributed by Galderma in North America, Dysport received FDA approval in 2009 and has been a fixture in aesthetic clinics for well over a decade. Its molecular structure features smaller particles than Botox, which allows it to diffuse more broadly after injection — a property that makes it particularly effective for large, flat treatment areas like the forehead.
This spreading quality is a double-edged sword: ideal when you want seamless softening across a wide zone, potentially problematic near delicate areas like the eyes.
Xeomin (IncobotulinumtoxinA)
Developed by Merz Pharmaceuticals, Xeomin was first approved by the FDA in 2010 for therapeutic use and later for cosmetic indications. It holds a unique position in the market as the "naked" neurotoxin — stripped of the accessory proteins that accompany botulinum toxin in every other brand.
The theoretical advantage is significant: without accessory proteins, there are no foreign proteins to trigger immune resistance. Patients who have noticed their Botox "wearing off faster" over years of repeated use — a phenomenon sometimes attributed to antibody formation — are frequently switched to Xeomin with good results.
Daxxify (DaxibotulinumtoxinA-lanm)
Revance Therapeutics launched Daxxify in the U.S. after FDA approval in September 2022, and it immediately created significant buzz by claiming something no prior neurotoxin had delivered: results that could last six to nine months. The secret is a proprietary peptide stabilizer (RTP004) that allows the toxin to bind more effectively and durably to nerve terminals. Daxxify is also the only neuromodulator that contains no human or animal-derived additives — a meaningful distinction for vegan and ethically motivated patients.
Head-to-Head Comparison: The Core Metrics
Onset of Action
Speed matters. Whether you're preparing for a wedding, a photoshoot, or simply dislike waiting, onset time is a practical consideration.
| Product | Typical Onset | Full Results |
|---|---|---|
| Letybo | 2–4 days | 7–10 days |
| Dysport | 1–3 days | 5–7 days |
| Xeomin | 3–5 days | 10–14 days |
| Daxxify | 1–3 days | 7–10 days |
Dysport and Daxxify are the speed leaders. Dysport's molecular structure allows faster diffusion, while Daxxify's peptide stabilizer appears to accelerate receptor binding. Xeomin tends to be the slowest of the group — not dramatically so, but notable if you need results quickly.
Duration of Results
This is where the conversation gets genuinely interesting — and where patient expectations most frequently diverge from reality.
| Product | Typical Duration | Clinical Trial Data |
|---|---|---|
| Letybo | 3–4 months | Comparable to Botox in BLESS trials |
| Dysport | 3–4 months | Consistent with other standard toxins |
| Xeomin | 3–4 months (up to 6 months in long-term users) | Some evidence of extended duration in repeat patients |
| Daxxify | 6–9 months | Median 6 months; 50% had no/minimal frown lines at 6 months in pivotal trials |
Daxxify is the unambiguous duration leader. Clinical studies submitted to the FDA showed that half of participants had little to no evidence of wrinkles six months after treatment, and about 10% maintained results up to nine months. That said, individual variation is real and significant — some patients metabolize Daxxify at the same rate as standard neurotoxins and see only three to four months of effect.
For Letybo, Dysport, and Xeomin, the standard three-to-four month window applies for most patients. Xeomin may edge slightly longer in patients who have used it for extended periods, possibly due to reduced antibody interference from its protein-free formula.
Spread and Diffusion
The degree to which a neurotoxin spreads beyond its injection point matters enormously depending on the treatment area.
High diffusion (Dysport): Excellent for the forehead and brow area where broad, even relaxation is desired. Less ideal near the eyes, where unintended spread could cause a drooping eyelid (ptosis).
Moderate diffusion (Letybo, Daxxify): Generally predictable and controllable with skilled injection technique.
Low diffusion (Xeomin): The most precise of the group. Preferred for delicate areas like crow's feet, the lips, and fine lines around the mouth where pinpoint accuracy is essential.
FDA-Approved Indications
| Product | Cosmetic Approvals | Medical Approvals |
|---|---|---|
| Letybo | Glabellar (frown) lines | None currently |
| Dysport | Glabellar lines | Cervical dystonia, upper/lower limb spasticity |
| Xeomin | Glabellar lines | Blepharospasm, cervical dystonia, upper limb spasticity, chronic sialorrhea |
| Daxxify | Glabellar lines | None currently (cervical dystonia trials were conducted) |
All four have their cosmetic FDA approval specifically for glabellar lines — the frown lines between the brows. In clinical practice, all are routinely used off-label for forehead lines, crow's feet, brow lifting, lip lines, jawline slimming, neck bands, and excessive sweating. Off-label use is legal and common, but patients should understand the distinction.
Deep Dive: Formulation Science and What It Actually Means for You
Understanding the molecular differences between these products helps explain why they behave differently in the body — and why the choice matters more than most people realize.
The Protein Question
Botulinum toxin type A is a neurotoxin naturally accompanied by accessory proteins (hemagglutinins and non-hemagglutinin proteins) when derived from bacteria. These proteins stabilize the toxin but also serve as potential targets for the immune system.
Xeomin removes all accessory proteins — it delivers the pure neurotoxin complex only. This is why it's called the "naked" toxin. The clinical implication: lower theoretical risk of antibody-induced resistance, making it a logical choice for patients who have used neurotoxins for many years and noticed diminishing returns.
Letybo retains fewer complexing proteins than Botox — not as minimal as Xeomin, but meaningfully reduced. Dermatologist Dr. Ellen Marmur has noted that with fewer protein targets available to the immune system, Letybo could theoretically last slightly longer in some patients or maintain efficacy better over repeated use.
Dysport and Daxxify both contain accessory proteins, but their stabilizing technologies differ. Daxxify's novel RTP004 peptide — which acts somewhat like a magnet to help the toxin adhere more strongly to nerve terminals — is responsible for its extended duration. This is fundamentally different from simply having more proteins; it's an engineered binding enhancement.
The Vegan Factor
Daxxify stands alone as the only FDA-approved neurotoxin formulated without any human serum albumin or animal-derived stabilizers. For patients with specific ethical concerns around biological sourcing, this is a meaningful differentiator that often goes undiscussed in clinical consultations.
Cost Comparison: Breaking Down the Real Numbers in 2026
Neurotoxin pricing is notoriously opaque, largely because units are not interchangeable between brands, and because geographic variation is significant. Here's a realistic breakdown as of 2026.
Price Per Unit
| Product | Average Cost Per Unit (US) | Units for Glabellar Lines | Estimated Treatment Cost |
|---|---|---|---|
| Letybo | $9–$13/unit | ~20 units | $180–$260 |
| Dysport | $4–$8/unit | ~50–60 units | $200–$480 |
| Xeomin | $10–$17/unit | ~20–25 units | $200–$425 |
| Daxxify | $12–$20/unit | ~40 units | $480–$800 |
Important caveat on Dysport: The lower per-unit price is misleading because Dysport requires approximately 2.5 to 3 times more units than Botox-comparable products to achieve the same effect. The final total treatment cost typically normalizes to a similar range.
Important caveat on Daxxify: While a single treatment is more expensive — sometimes significantly so — the extended duration means fewer annual treatments. For someone who would otherwise get Botox four times per year, switching to Daxxify at twice per year could result in comparable or even lower annual spending, while also requiring fewer clinic visits.
Annual Cost of Treatment: A Realistic Model
Assuming glabellar line treatment only, three to four sessions per year for standard neurotoxins and two sessions for Daxxify:
| Product | Sessions/Year | Cost Per Session | Annual Spend (Estimate) |
|---|---|---|---|
| Letybo | 3–4 | $200–$260 | $600–$1,040 |
| Dysport | 3–4 | $250–$480 | $750–$1,920 |
| Xeomin | 3–4 | $200–$425 | $600–$1,700 |
| Daxxify | 1–2 | $480–$800 | $480–$1,600 |
Letybo emerges as notably cost-competitive, particularly for patients who want high-quality results without Botox's brand premium. Daxxify's economics improve substantially when you factor in reduced session frequency.
Real-World Reviews and Patient Experiences
Clinical trial data tells one part of the story. What patients actually report after treatment tells another — often revealing nuances that controlled studies can't capture.
Letybo: The New Contender
Early adopters in the U.S. — many of whom were already familiar with Botulax from medical tourism in South Korea — consistently describe Letybo as delivering results that are "soft and natural-looking" with a rapid onset. At clinics that have introduced it alongside Botox and Jeuveau, patient satisfaction data is tracking comparably.
Board-certified dermatologist Dr. Sue Ellen Cox, who was an investigator in Letybo's clinical trials, described it plainly: "It's going to work just as well as Botox, but we're not going to see a big difference when it comes to patients being able to distinguish it from other neuromodulators." The key selling point isn't superiority — it's competitive quality at a more accessible price point.
Dysport: The Forehead Favorite
Among injectors, Dysport has a devoted following specifically for forehead treatment. Its natural spreading quality can eliminate the "banded" or "patchwork" effect that occasionally results from precise-point injection with other toxins. Patients who want seamlessly smooth foreheads — the kind that look naturally expressive rather than injected — often report high satisfaction with Dysport.
The tradeoff: results near the orbital area require an experienced, careful injector. Dysport in less skilled hands is more likely to produce ptosis (drooping eyelid) than toxins with tighter diffusion.
Xeomin: The Steady Performer for Long-Term Users
Xeomin attracts a specific type of patient: someone who has been getting neurotoxin treatments for years and is frustrated that results seem to be fading faster than they used to. The absence of accessory proteins theoretically reduces the likelihood that repeated exposure will trigger the immune response that makes other neurotoxins less effective over time.
Long-term users frequently report that switching to Xeomin "refreshes" their results, and many injectors recommend cycling patients between Botox and Xeomin every few years precisely for this reason.
Daxxify: The Duration Disruptor
Patient reviews of Daxxify split along a predictable line: those who experience the promised six-month or longer duration are enthusiastic advocates, while those who metabolize it quickly — seeing only three to four months of effect — feel let down despite knowing this variability was disclosed upfront.
The American Society of Plastic Surgeons highlights Daxxify's faster onset (one to two days versus Botox's ten to fourteen) as a genuine practical benefit. For patients who dislike the waiting period after injection, this alone is a compelling reason to choose it.
Pros and Cons Summary
Letybo
Pros: Competitive pricing, fewer complexing proteins than Botox, rapid onset (2–4 days), strong international track record (7 years as South Korea's #1 neurotoxin), excellent safety profile in clinical trials, possible long-term resistance advantage.
Cons: Newest to the U.S. market (launched 2024), fewer injectors with extensive hands-on Letybo experience, currently approved only for glabellar lines, no loyalty/rewards program as established as Allergan's Allē.
Dysport
Pros: Fastest onset among standard toxins (1–3 days), excellent for large areas like the forehead, decades of clinical data, widely available, well-understood diffusion properties for skilled injectors.
Cons: Higher diffusion increases risk in delicate areas, requires significantly more units (making transparent cost comparison tricky), may not suit patients wanting precise targeted treatment.
Xeomin
Pros: Only protein-free neurotoxin (reduced resistance risk), ideal for sensitive patients, precise low-diffusion action, strong long-term safety record, competitive pricing, FDA-approved for multiple medical conditions.
Cons: Slower onset than competitors, doesn't noticeably outperform others in head-to-head comparisons in treatment-naive patients, slightly more sensitive to storage/handling.
Daxxify
Pros: Longest duration on the market (6–9 months for many patients), fast onset (1–2 days), no animal-derived ingredients, fewer annual treatments, potentially cost-efficient on an annual basis.
Cons: Most expensive per session, individual variation means some patients won't experience extended duration, any unwanted effects also last longer, limited approval history compared to established brands.
Which Lasts the Longest? The Definitive Answer
Daxxify wins clearly on duration for the majority of patients, with clinical data supporting a median of six months and some patients experiencing up to nine months of effect. No other FDA-approved neurotoxin currently approaches these numbers.
Among the remaining three, the differences are modest. Standard Botox-comparable durations of three to four months apply to Letybo and Dysport. Xeomin may edge slightly longer in long-term users, but this is an emerging clinical observation rather than consistently demonstrated data.
The nuance that matters: Duration is deeply individual. Metabolism rate, muscle mass and strength in the treatment area, treatment frequency, and even fitness level (high-intensity exercisers tend to metabolize neurotoxins faster) all influence how long results last. Clinical trial data reports medians and ranges — guarantees don't exist in this field.
Who Should Choose What? A Decision Framework
Choosing between these four products isn't just about which one is "best." The right choice is contextual.
Choose Letybo if:
You want modern, proven results at a competitive price point and are comfortable with a newer-to-U.S. brand with a strong international track record. Ideal for first-timers who don't want to pay a Botox brand premium, or for experienced patients interested in the theoretical benefits of reduced complexing proteins.
Choose Dysport if:
Your primary concern is forehead smoothing and you want natural, seamless results across a large area. Also a strong choice if quick onset is important — Dysport is one of the fastest-acting options available. Requires working with an experienced injector who understands its diffusion characteristics.
Choose Xeomin if:
You've been using neurotoxins for years and feel they're working less effectively than they used to. The protein-free formula makes Xeomin the logical choice for patients concerned about antibody resistance. Also ideal for precise, targeted treatment of delicate areas.
Choose Daxxify if:
You want maximum duration above all other factors, you hate clinic visits, you're planning around a major life event, or you're ethically motivated by the absence of animal-derived ingredients. Budget for the higher per-session cost but recognize the potential savings from reduced treatment frequency.
Safety Profile: What to Know About Side Effects
All four neurotoxins share a similar FDA-mandated black box warning: the effects of botulinum toxin may spread beyond the injection site in rare cases, producing symptoms consistent with generalized botulinum toxicity. This risk is present for all products and applies primarily to doses far exceeding cosmetic amounts.
At standard cosmetic doses, the safety profiles are broadly comparable:
Most common side effects across all four products:
- Headache (most frequently reported, typically mild and self-resolving)
- Bruising at injection site
- Temporary redness or swelling
- Injection-site discomfort
Product-specific considerations:
- Dysport: Slightly higher theoretical risk of unintended muscle relaxation in adjacent areas due to diffusion
- Daxxify: Any side effects — including undesired ones — will persist longer given the extended duration
- Xeomin: Some evidence suggests fewer allergy-related reactions due to absence of accessory proteins
- Letybo: No serious adverse events attributable to distant toxin spread were reported in clinical studies at cosmetic doses
None of these products are appropriate during pregnancy or breastfeeding, and all require disclosure of other neurotoxin treatments received within the previous four months.
Frequently Asked Questions
1. Can I switch between Letybo, Dysport, Xeomin, and Daxxify freely?
Yes, but with one important caveat: units are not interchangeable. Each product has its own potency measurement calibrated to its proprietary biological assay. Dysport requires roughly 2.5 to 3 times as many units as the others for an equivalent effect. Your injector will recalibrate dosing when switching — this is routine practice.
2. Does Daxxify actually last 9 months for everyone?
No. Clinical trials showed that the median duration was approximately six months, with about 10% of participants maintaining results up to nine months. A meaningful subset of patients metabolizes Daxxify at rates similar to standard neurotoxins and sees three to four months of effect. Individual biological variation is the primary driver, and no provider can guarantee duration in advance.
3. Is Letybo safe? It's so new in the U.S.
Letybo is FDA-approved based on three Phase III clinical trials involving more than 1,000 subjects — a robust dataset. It has also been used safely in South Korea, Europe, and other markets for years before its U.S. launch. The FDA's own review concluded that its safety profile is comparable to other approved botulinum toxin A products. "New in the U.S." does not mean untested.
4. Why do some people develop resistance to neurotoxins, and which product is least likely to cause this?
Resistance occurs when the immune system generates antibodies against botulinum toxin or its accompanying proteins, reducing the product's effectiveness over time. Xeomin — with no accessory proteins — offers the lowest theoretical risk of this response. Letybo's reduced protein profile also provides some theoretical advantage over traditional Botox formulations. Resistance is relatively uncommon but more likely with frequent high-dose use or repeated treatment within short intervals.
5. Is Daxxify worth the higher cost?
This depends entirely on how you value time and convenience versus upfront expense. If you currently receive neurotoxin treatment four times per year, switching to Daxxify could reduce that to twice per year — cutting your clinic visits in half. At comparable annual spending, the convenience gain alone may justify the choice. For patients who genuinely don't respond to Daxxify with extended duration, the cost-benefit equation is less favorable.
6. Which neurotoxin gives the most "natural-looking" results?
This is largely a function of injection technique rather than product formula. That said, product characteristics do play a role. Dysport's natural diffusion can create seamlessly smooth forehead results without visible injection points. Letybo is frequently described as producing a "soft finish." Daxxify users report results that look comparable to Botox cosmetically, with the added practical benefit of longevity.
7. Can neurotoxins be combined with dermal fillers?
Yes, and combination treatment is extremely common. Neurotoxins address dynamic wrinkles caused by muscle movement, while fillers (hyaluronic acid, etc.) restore volume and smooth static wrinkles. Many patients receive both in the same session, a treatment sometimes called a "liquid facelift." Your provider should assess your facial anatomy holistically before recommending a combination approach.
Key Takeaways
The neurotoxin landscape in 2026 is more sophisticated and more competitive than at any point in its history. The right choice isn't the most expensive option or the newest brand — it's the one that aligns with your specific treatment goals, budget, lifestyle, and anatomy.
Here's how to remember the core distinctions:
- Letybo = Quality at competitive cost, reduced protein profile, strong international track record, ideal for value-conscious patients
- Dysport = Speed and spread, best for large-area forehead treatment, requires skilled injector hands
- Xeomin = Purity and precision, the smart choice for long-term users concerned about resistance
- Daxxify = Duration and convenience, the clear leader if fewer annual treatments is your top priority
None of these products is universally superior. Each fills a distinct niche. The most important single factor in your outcome, beyond product choice, is the skill, experience, and anatomical knowledge of your injector. An exceptional injector with Dysport will consistently outperform a mediocre injector with Daxxify.
Consult with a board-certified dermatologist or plastic surgeon. Ask specifically about their experience with all available products. And approach any provider who insists that only one neurotoxin is "the best" with appropriate skepticism — that's a marketing position, not a medical one.